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Cell derived extracellular vesicles are submicron structures surrounded by phospholipid 
bilayer, and released by both prokaryotic and eukaryotic cells.  The sizes of these vesicles 
roughly fall into the size ranges of microbes, and they represent efficient delivery platforms 
targeting complex molecular information to professional antigen presenting cells.  Critical 
roles of these naturally formulated units of information have been described in many 
physiological and pathological processes. Extracellular vesicles are not only potential 
biomarkers and possible pathogenic factors in numerous diseases, but they are also considered 
as emerging therapeutic targets and therapeutic vehicles.  Strikingly, current drug delivery 
systems, designed to convey therapeutic proteins and peptides (such as liposomes), show 
many similarities to extracellular vesicles. Here we review some aspects of therapeutic 
implementation of natural, cell-derived extracellular vesicles in human diseases. Exploration 
of molecular and functional details of extracellular vesicle release and action may provide 
important lessons for the design of future drug delivery systems.  
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Over the past few decades experimental data started to accumulate in support of the existence 
of extracellular vesicles (EVs) in the size range earlier thought to be occupied only by 
microorganisms.  It is only recently that the universality of EV secretion has been recognized 
by the exploration of vesiculation also in prokaryotes [1-3]. The microorganism-sized EVs are 
readily taken up by cells of the immune system. Of note, many of these vesicles are released 
during apoptosis, and the immune system’s “high throughput” homeostatic clearance 
machinery for the uptake of vesicles of apoptotic origin is highly efficient. This process is 
mediated by phagocyte receptors (e.g. phosphatidyl serine receptor, TIM-4 or TAM receptors 
[4, 5] ensuring the rapid internalization of EVs by cells. Importantly, endocytosis is not the 
only uptake mechanism of EVs. Direct fusion of their membrane with the plasma membrane 
of specifically recognized cells has been suggested as another uptake mechanism (for recent  
review see [6].  In this case the content of EVs is released directly into the cytoplasm of the 
targeted cell [7]. The efficient cellular uptake renders EVs attractive candidate vehicles to 
deliver selected molecules to cells.  
There is a striking analogy between currently used pharmaceutical drug delivery systems such 
as liposomes or microparticles designed to deliver proteins or peptides (Figures 1 and 2). In 
general, encapsulation of molecules for targeted delivery provides protection against 
enzymatic degradation, aggregation, or precipitation. Also, encapsulation ensures high local 
concentration of substances at a distant, targeted site. It is tempting to speculate that the 
phospholipid bilayer “capsule” of cell-derived EVs serves similar biological purposes. In line 
with this hypothesis, recently, EVs have been suggested to function as multipurpose carriers i) 
to deliver complex information to other cells ii) for safe removal of potentially harmful 
molecules and iii) aiding and extending functions of the donor cells [8].  
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In contrast to liposomes, EVs are derived from cells of the body, thus, they are composed of 
self molecules tolerated by the immune system. They can be used for prolonged time safely. 
On the other hand, liposomes may be manufactured in large scale synthetically at relatively 
low expenses.  
In the current article, we aim at briefly summarizing some basic concepts and therapeutic 
implications of EVs to attract attention to a rapidly evolving field that emerges in parallel with 
development of nanomedicines as drug delivery systems.  We propose that novel therapeutic 
strategies may benefit from lessons of the evolutionary conserved, natural vesicular structures. 
Overview of EVs 
Classification and nomenclature of cell derived EVs   
It has been suggested that major subpopulations of EVs include exosomes, microvesicles and 
apoptotic bodies [9]. 
Multivesicular bodies (MVBs) of the endocytotic compartment fuse with the plasma 
membrane, and release vesicles (50-100 nm in diameter) designated as exosomes [10, 11]. 
Another pathway of vesicle release involves budding of the plasma membrane with ultimate 
release of membrane surrounded vesicles referred to as microvesicles (MVs) often referred to 
as microparticles or ectosomes [12].  While the size range of exosomes roughly overlaps with 
that of viruses, vesicles, generated by budding, have larger diameter (100-1000 nm) 
corresponding approximately to the size range of bacteria or insoluble immune complexes [9, 
13]. While exosomes are generated both constitutively and upon activation, the release of 
microvesicles is induced during apoptosis and activation [7, 9]. Both major types of EVs are 
encapsulated by a phospholipid bilayer membrane rich in cholesterol.  
5 
 
However, recent evidences support that there are numerous further subtypes of EVs. As an 
example, Théry et al. provided evidence for the existence of diverse populations secreted 
by different intracellular mechanisms [14]. 
As yet there is no international consensus regarding the terminology of EVs [15]. 
 
Detection methods of EVs 
 
Detection of EVs imposes significant challenge on cell biologists, since conventional/ routine 
cell biology methodologies can not be applied for the investigation of these subcellular 
structures. Fluorescence microscopy and flow cytometry cannot be used for the analysis of 
exosomes, unless the vesicles are bound onto the surface of beads [16]. The analysis of not 
only exosomes but also of larger sized MVs, have limitations with conventional techniques. 
Flow cytometry fails to detect structures with less than 2-300 nm in diameter. Methodologies, 
used to characterize pharmaceutical liposome or microparticle/nanoparticle preparations, are 
more appropriate for studying cell derived EVs. 
Transmission electron microscopy (in particular immune electron microscopy) has proven 
very useful for the detection and analysis of cell-derived vesicles irrespective of their size [17, 
18]. Electron microscopy of exosomes shows a so called “cup shape” after isolation by 
sucrose gradient/cushion ultracentrifugation (that was suggested to be an artifact of 
preparation), while microvesicles are characterized by spherical shape with cryo- transmission 
electron microscopy [19]. Cryo-electron tomography microsopy was shown to be useful to 
avoid such types of artifacts [20, 21]. Also, scanning electron microscopy [22] single particle 
electrom microscopy [23] and atomic force microscopy was used successfully to visualize 
individual EVs [13, 22]. Further non-conventional techniques of analysis (suitable for the 
analysis of EVs and liposomes)  include dynamic light scattering analysis (DLS), nanoparticle 
6 
 
tracking analysis (NTA) [24, 25] and Fluorescence Nanoparticle Tracking Analysis (F-NTA) 
[26], Raman spectroscopy based techniques, Stimulated Emission Depletion (STED) 
microscopy, Impedance-based flow cytometry  and resistive pulse sensing [27]. Presumably, 
the increasing demands of this research field will boost the development of further specific 
methodologies and user-friendly laboratory instruments fitted to the size range of EVs.  
 
Biological functions      
 
EVs are important rescently recognized players of intercellular communication [12, 27, 28]. 
They are known to disseminate, support, and protect basic biological functions of the 
releasing cells. Exosomes have been shown to mediate horizontal transfer of mRNA, miRNA 
[29] and different types of cell surface receptors such as an oncogenic receptor [30] or 
purinergic P2X7 receptor [31]. One of the most important functions described in association 
with exosomes, is antigen presentation, a function earlier attributed to antigen presenting cells 
only [32]. Exosomes display both MHC-I and MHC-II molecules on their surface assembled 
with antigenic peptides. This feature has significant impact on the ability of EVs (such as 
exosomes) to induce immune responses upon injection as vaccines [33, 34]. Consequently,  
immunoregulation (including either stimulation or inhibition) is a principal function of 
exosomes, depending on the cellular source and target of the vesicles [12]. This feature raises 
the intriguing possibility of therapeutic immune modulation by exosomes.  
Although immune regulatory functions of the larger sized MVs have also been reported  (e.g. 
in the fetomaternal communication [35]), their best characterized function is the one they play 
in blood coagulation:  they have significant procoagulant activity [36-39]. Similarly to 
exosomes, MVs represent a form of secretion of IL1 beta [31, 40] and have been suggested to 
contribute to the pathogenesis of rheumatoid arthritis [41, 42]. By their protease [43], and 
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possibly also by their glycosidase expression [44], MVs may contribute to the proinvasive 
character of tumors.   
 
Therapeutic targeting of EVs 
A few years after that the original concept of liposomes was raised by Bangham et al. in 1965 
[45], these artificial lipid vesicles were suggested to be used as drug carriers [46], and a novel 
drug delivery system, liposomal encapsulation of drugs, has been introduced [47]. Currently, 
in the „nano era”, liposomes are frequently referred to as nanoparticles, and their use 
represents an organic part of nanomedicine. However, besides all benefits of engineered 
liposomes (in the case of which biocompatibility and biodegradability is evident), the use of 
EVs may be more favorable. These nature-encapsulated subcellular structures have been 
suggested  for therapeutical delivery of molecules [48] and it may represent novel tools in 
future personalized medicine and in efficient and site-specific delivery of therapeutic drugs or 
nucleic acids.  
Moreover, secreted EVs are not only nature-tailored carrier vehicles with potential therapeutic 
exploitation, but they also represent promising drug targets. As mentioned above, a wide 
variety of human diseases are characterized by elevated numbers and altered composition of 
circulating EVs. While in some cases their increased number may reflect general cellular 
activation or enhanced apoptosis, EVs may also substantially contribute as effectors to disease 
development.  They were shown to contribute to tumor growth, migration and invasion, 
angiogenesis and tumor escape from immune responses (reviewed recently [49]. Therefore 
prevention of EV release or therapeutic removal of released vesicles from the circulation 
might also represent a therapeutic approach.  
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Tumor-derived exosomes are known biologic messengers in cancers, are mediators of 
tolerance induction and are shown to spread tumor growth signals that counteract the activity 
of therapeutic agents [50]. Therefore, therapeutic targeting of tumor cell derived exosomes 
represent an important therapeutic approach. The extracorporeal haemofiltration of circulating 
factors as a therapeutic strategy is already approved to be used in cancer patients [50]. 
 
EVs of pathogens in health and disease 
Functional virus release has been reported to involve several elements from the EV biogenesis 
patways [51]. EVs have been shown to play either enhancing or blocking roles in infections 
and and represent removal systems for endogenous retroviruses or retrotransposons [51]. 
Recently, fraction of Adeno associated virus (AAV) vectors have been shown to be  
associated with EVs(vector-exosomes) and have been suggested for improved  promising 
strategy to improved gene delivery [52].  
EVs have been demonstrated to be secreted by Gram-negative [53, 54] and Gram-positive 
bacteria [55, 56], as well as eukaryotic parasites of the kinetoplast lineage and 
opportunistic fungi of both the ascomycetes and basidiomycetes lineages [57]. 
Outer membrane vesicles (OMVs) of many pathogenic bacteria contribute to the virulence of 
the releasing bacterial cells. Importantly, OMVs have been recently suggested to serve as a 
basis of non-replicating vaccines summarized by Ünal et al. [58]. 
A disease in which EV vaccination was proposed is sepsis, associated with increased 
proinflammatory cytokine levels and the accumulation of apoptotic cells. In the toxoplasmic 
model of sepsis, Toxoplasma gondii-pulsed Dex could stimulate a specific and protective T-
cell response in CBA/J mice [59]. Although the mechanism remained unclear, and 
presumably activators of DCs, B-, T or NK cells may have contributed to the efficacy of 
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exosomes against Toxoplasma gondii infection in this congenital model, Dex appears  to be a 
potentially useful tool for vaccination in sepsis.  
In other models, exosomes derived from immature dendritic cells rescued septic animals 
because of the presence of milk fat globule epidermal growth factor (EGF)-factor VIII (MFG-
E8) on their surface. MFG-E8 is required to opsonise cells for phagocytosis, which has to be 
promoted in septic animals to prevent the release of the potentially harmful substances from 
dying cells. An increased phagocytosis eventually reduces mortality, and attenuates the 
release of proinflammatory cytokines in the septic rats [60]. 
Conclusions 
The ubiquitous feature of vesiculation by both eukaryotes and prokaryotes, has been 
established only recently. Both Gram negative and positive bacteria as well as fungi were 
shown to release these structure, and more recently, also the significance of plant derived 
apoplastic exosome-like vesicles have been suggested [61]. 
It is currently a unique situation that cell-derived EVs can be considered both as novel drug 
targets and natural drug delivery systems. 
Unfolding diseases in which EVs play effector roles, may lead to development of EV 
targeting therapeutic strategies (such as prevention of vesicle relase or to removal of secreted 
ones).  On the other hand, manufacturing EVs for therapeutic applications is feasible in vitro 
inducing vesicle secretion by various stimuli. In vitro manipulation (e.g.  transfection)  of the 
releasing cells provides unique opportunity to produce tailored EVs with customized effector 
or targeting molecules. Vesicles, harvested from tissue culture supernatants, may be injected 
to modulate immune functions or to vaccinate against epitopes presented on vesicular surfaces 
in the context of MHC molecules. EVs are of proper size for uptake by cells, non-toxic, 
biodegradable, carry surface molecules that direct them to targeted cells, and carry complex 
10 
 
information. To date, especially exosomes have been shown to have a great potential. 
However, larger sized MVs, currently considered as biomarkers in body fluids such as blood 
plasma, urine or saliva, are far less characterized, and may hold  yet unexplored therapeutic or 
vaccination potential. Vaccination by EVs or removal of circulating exosomes by 
haemofiltration are the types of exploitation of EVs have been already introduced to clinical 
practice.   
A recent study has directly compared liposomes and exosomes as drug delivery systems for 
encapsulation curcumin in them. In a proof-of-principle study of Sun et al. it has been 
demonstrated that encapsulation of the antiinflammatory agent curcumin in exosomes was 
significantly superior to liposomal delivery as shown by the enhanced stability and  higher 
concentration in the blood as well as higher therapeutic efficacy in (LPS)-induced septic 
shock mouse model [62].   
Even though EVs may offer novel opportunities for prevention or therapeutic intervention in 
disease states in which patients do not respond to conventional therapies, one has to be aware 
of the risks also. Given that viruses and exosomes share size distribution and other 
biophysical parameteres, concerns center on potential contamination of exosome preparations 
with viruses. Development of safe technologies of large scale production of virus-free 
exosomal preparations is an absolute prerequisite of their therapeutic exploitation.  
What appears to be clear is that is that researchers developing artificial drug delivery systems 
and those exploring EVs need to have an intense communication, and they should both follow 
the progress in the other field. The two scientific communities must recognize the possible 
mutual benefits of such an interaction.  EV scientists have already taken advantage of 
methodologies originally used for the characterization of microbes, liposomes or other 
nanoparticles (such as DLS, AFM or NTA). Proof for the benefit for drug developers is best 
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examplified by the recent development of artificial exosomes. These are liposomes coated 
with MHC/peptide complexes and Fab regions against T cell receptors to mediate cell surface 
adhesion [63, 64]. Presumably many further experiments will be inspired by lessons of natural 
EVs that successfully overcame evolutional challenges. Studies focusing on nanomedicinal 
drug delivery systems and nature-tailored vesicules may cross-fertilize one another, and may 
lead to novel therapeutical solutions.  
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Figure.2. Cryo-electron microscopic image of liposomes (A) 
(http://www.mardre.com/homepage/mic/tem/samples/colloid/pc_samples/dmpc_liposome_cry
o3.jpg) and 5/4 T hybridoma cell exosomes  (B) show high similarity in both size distribution 
and their shape 
 
